Brief: Achieve Life Sciences Conducts Pre-New Drug Application Meeting With FDA For Drug Product, Cytisinicline
Dec 11 (Reuters) - Achieve Life Sciences Inc ACHV.O :
* ACHIEVE LIFE SCIENCES INC - RECENTLY CONDUCTED PRE-NEW
DRUG
APPLICATION MEETING WITH FDA FOR COMPANY'S DRUG PRODUCT
CANDIDATE, CYTISINICLINE
* ACHIEVE LIFE SCIENCES: IN ONGOING TALKS WITH FDA TO
CLARIFY
REQUIREMENTS AND TIMING FOR LONG-TERM EXPOSURE SAFETY DATA TO
SUPPORT NDA SUBMISSION
* ACHIEVE LIFE SCIENCES INC - COMPANY'S NDA FILING TIMING
MAY BE
DELAYED TO ADDRESS FDA FEEDBACK
Further company coverage: ACHV.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock